BTIG Research Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock

Key Points

• BTIG Research has raised its price target for Stoke Therapeutics from $28.00 to $39.00, indicating a potential upside of 28.54% from the previous close.
• Stoke Therapeutics recently reported a quarterly earnings loss of ($0.40) EPS, which beat analysts' estimates of ($0.57) by $0.17.
• Insider selling activity includes General Counsel Jonathan Allan and Director Edward M. Md Kaye, who have decreased their holdings in the company significantly, reflecting a potential shift in sentiment.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) had its price objective increased by investment analysts at BTIG Research from $28.00 to $39.00 in a report released on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's price objective would indicate a potential upside of 28.54% from the stock's previous close.

Several other research analysts have also commented on the stock. Chardan Capital reissued a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Stoke Therapeutics in a report on Wednesday, October 8th. Needham & Company LLC raised their target price on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a "buy" rating in a report on Friday. Finally, Wedbush raised their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $30.83.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $30.34 on Monday. The firm has a 50 day simple moving average of $21.32 and a 200-day simple moving average of $14.08. Stoke Therapeutics has a one year low of $5.35 and a one year high of $32.40. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 35.69 and a beta of 1.24.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The business had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Equities analysts predict that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Jonathan Allan sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total transaction of $250,700.00. Following the transaction, the general counsel directly owned 11,831 shares in the company, valued at approximately $296,603.17. This trade represents a 45.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward M. Md Kaye sold 25,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $30.00, for a total transaction of $750,000.00. Following the transaction, the director owned 49,124 shares in the company, valued at approximately $1,473,720. This trade represents a 33.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 185,180 shares of company stock valued at $4,129,406. 9.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. GAMMA Investing LLC grew its position in Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after buying an additional 5,084 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Stoke Therapeutics during the 1st quarter worth $72,000. Finally, US Bancorp DE boosted its position in shares of Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after purchasing an additional 11,108 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.